120 related articles for article (PubMed ID: 35114775)
21. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
[TBL] [Abstract][Full Text] [Related]
22. FISHing for 1p19q codel in oligodendroglioma.
Kong PL; Cheah PL; Mun KS; Chiew SF; Lau TP; Koh CC; Teoh KH; Nazarina AR; Looi LM
Malays J Pathol; 2020 Dec; 42(3):369-376. PubMed ID: 33361717
[TBL] [Abstract][Full Text] [Related]
23. [Significance and prospects of study on molecular alterations in oligodendrogliomas].
Gresner SM; Liberski PP
Neurol Neurochir Pol; 2007; 41(4):333-9. PubMed ID: 17874342
[TBL] [Abstract][Full Text] [Related]
24. Alpha-internexin expression in gliomas: relationship with histological type and 1p, 19q, 10p and 10q status.
Durand K; Guillaudeau A; Pommepuy I; Mesturoux L; Chaunavel A; Gadeaud E; Porcheron M; Moreau JJ; Labrousse F
J Clin Pathol; 2011 Sep; 64(9):793-801. PubMed ID: 21653654
[TBL] [Abstract][Full Text] [Related]
25. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours.
Kim JW; Park CK; Park SH; Kim YH; Han JH; Kim CY; Sohn CH; Chang KH; Jung HW
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):224-7. PubMed ID: 20587495
[TBL] [Abstract][Full Text] [Related]
26. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
McNamara MG; Jiang H; Lim-Fat MJ; Sahebjam S; Kiehl TR; Karamchandani J; Coire C; Chung C; Millar BA; Laperriere N; Mason WP
Can J Neurol Sci; 2017 May; 44(3):288-294. PubMed ID: 28488951
[TBL] [Abstract][Full Text] [Related]
27. Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component.
Takeuchi H; Kubota T; Kitai R; Matsuda K; Hashimoto N; Sato K
J Neurooncol; 2009 Jan; 91(1):33-8. PubMed ID: 18781279
[TBL] [Abstract][Full Text] [Related]
28. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
29. Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.
Ren X; Jiang H; Cui X; Cui Y; Ma J; Jiang Z; Sui D; Lin S
Neuro Oncol; 2013 Sep; 15(9):1244-50. PubMed ID: 23861470
[TBL] [Abstract][Full Text] [Related]
30. Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
Hirose T; Ishizawa K; Shimada S
Neuropathology; 2010 Dec; 30(6):586-96. PubMed ID: 20408960
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.
Aldape K; Burger PC; Perry A
Arch Pathol Lab Med; 2007 Feb; 131(2):242-51. PubMed ID: 17284109
[TBL] [Abstract][Full Text] [Related]
32. Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography.
Iwadate Y; Shinozaki N; Matsutani T; Uchino Y; Saeki N
J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):1016-21. PubMed ID: 26848169
[TBL] [Abstract][Full Text] [Related]
33. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype.
Smith JS; Alderete B; Minn Y; Borell TJ; Perry A; Mohapatra G; Hosek SM; Kimmel D; O'Fallon J; Yates A; Feuerstein BG; Burger PC; Scheithauer BW; Jenkins RB
Oncogene; 1999 Jul; 18(28):4144-52. PubMed ID: 10435596
[TBL] [Abstract][Full Text] [Related]
34. False-positive 1p/19q Testing Results in Gliomas: Clinical and Research Consequences.
Alnahhas I; Rayi A; Thomas D; Ong S; Giglio P; Puduvalli V
Am J Clin Oncol; 2020 Nov; 43(11):802-805. PubMed ID: 32889892
[TBL] [Abstract][Full Text] [Related]
35. Loss of genetic material within 1p and 19q chromosomal arms in low grade gliomas of central nervous system.
Ręcławowicz D; Stempniewicz M; Biernat W; Limon J; Słoniewski P
Folia Neuropathol; 2013; 51(1):26-32. PubMed ID: 23553134
[TBL] [Abstract][Full Text] [Related]
36. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Oncomine Comprehensive Assay v3 panel for the detection of 1p/19q codeletion in oligodendroglial tumours.
Ali RH; Alateeqi M; Jama H; Alrumaidhi N; Alqallaf A; Mohammed EM; Almurshed M; Bahzad S
J Clin Pathol; 2023 Feb; 76(2):103-110. PubMed ID: 34489310
[TBL] [Abstract][Full Text] [Related]
38. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
[No Abstract] [Full Text] [Related]
39. Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma.
McLendon RE; Rasheed A; Wiltshire R; Herndon J
Mod Pathol; 2004 May; 17(5):604-5. PubMed ID: 15105803
[No Abstract] [Full Text] [Related]
40. Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.
Choi KY; Jung TY; Jung S; Kim YH; Moon KS; Kim IY; Kang SS; Lee KH
J Neurooncol; 2011 May; 103(1):103-10. PubMed ID: 20737192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
